Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

  • Details

ClinicalTrials.gov ID: NCT03975647
Diagnosis Type: Breast Cancer
USOR Number: 19054

  • Practice Details

3410 Worth Street, Suite 400
Dallas, TX 75246
1 miles away
P: (214) 370-1300 P: (214) 370-1300

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced orMetastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer (ODO-TE-B202)

  • Details

ClinicalTrials.gov ID: NCT03952325
Diagnosis Type: Breast Cancer
USOR Number: 19009

  • Practice Details

3410 Worth Street, Suite 400
Dallas, TX 75246
1 miles away
P: (214) 370-1300 P: (214) 370-1300

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)

  • Details

ClinicalTrials.gov ID: NCT03901339
Diagnosis Type: Breast Cancer
USOR Number: 18282

  • Practice Details

3410 Worth Street, Suite 400
Dallas, TX 75246
1 miles away
P: (214) 370-1300 P: (214) 370-1300

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)

  • Details

ClinicalTrials.gov ID: NCT03858972
Diagnosis Type: Breast Cancer
USOR Number: 18238

  • Practice Details

3410 Worth Street, Suite 400
Dallas, TX 75246
1 miles away
P: (214) 370-1300 P: (214) 370-1300

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

  • Details

ClinicalTrials.gov ID: NCT03310957
Diagnosis Type: Breast Cancer
USOR Number: 18004

  • Practice Details

3410 Worth Street, Suite 400
Dallas, TX 75246
1 miles away
P: (214) 370-1300 P: (214) 370-1300

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

  • Details

ClinicalTrials.gov ID: NCT03725059
Diagnosis Type: Breast Cancer
USOR Number: 17188

  • Practice Details

3410 Worth Street, Suite 400
Dallas, TX 75246
1 miles away
P: (214) 370-1300 P: (214) 370-1300

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

  • Details

ClinicalTrials.gov ID: NCT03053193
Diagnosis Type: Breast Cancer
USOR Number: 17079

  • Practice Details

3410 Worth Street, Suite 400
Dallas, TX 75246
1 miles away
P: (214) 370-1300 P: (214) 370-1300

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

  • Details

ClinicalTrials.gov ID: NCT03262935
Diagnosis Type: Breast Cancer
USOR Number: 17027

  • Practice Details

3410 Worth Street, Suite 400
Dallas, TX 75246
1 miles away
P: (214) 370-1300 P: (214) 370-1300

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)

  • Details

ClinicalTrials.gov ID: NCT01969643
Diagnosis Type: Breast Cancer
USOR Number: 16104

  • Practice Details

3410 Worth Street, Suite 400
Dallas, TX 75246
1 miles away
P: (214) 370-1300 P: (214) 370-1300

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

  • Details

ClinicalTrials.gov ID: NCT03975647
Diagnosis Type: Breast Cancer
USOR Number: 19054

  • Practice Details

1441 N Beckley Ave, Suite 102
Dallas, TX 75203
2 miles away
P: (214) 943-9911 P: (214) 943-9911

More Details View Practice Page
1 2 3 … 9

Find a Location

With more than 2,500 physicians and over 600 treatment locations across the country, the advanced cancer care you need may be available right in your local community from a practice in The US Oncology Network. Search to see if there is a center near you.